Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3981-3990 Newer>

Managed Care July 2007 John Marcille	Perverse Incentives Abound, But Maybe We Can Control Them With all the intellectual capital working on the problem of provider compensation, you'd think perverse incentives would be curbed.
Managed Care July 2007 R. Knight Steel	Incentives Work Against Proper Elder Care The health care system encourages a reaction to episodes that is both costly and inefficient.
Managed Care July 2007 John Carroll	Unlocking a Trove of Quality Data A bill before Congress would give analysts a powerful tool for sifting through Medicare data on the performance of hospitals and physicians.
Managed Care July 2007	AMA: Patients Will Feel Cuts in Medicare Next year's proposed 10 percent cut in Medicare payments is serving as a rallying point for members of the American Medical Association, which says the cuts will make it difficult for physicians to accept new Medicare patients.
Managed Care July 2007	The Formulary Files Chronic disease treatments contribute significantly to spending growth.
Managed Care July 2007	Managed Care Outlook The future holds too few docs.
The Motley Fool August 3, 2007 Brian Lawler	Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown.
The Motley Fool August 3, 2007 Brian Orelli	Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug.
The Motley Fool August 3, 2007 Brian Lawler	Vanda Announces Some Late-Stage Maneuvers Vanda Pharmaceuticals gets ready for a busy remainder of 2007. Management awaits approval on three different compounds in the near future. Investors should be prepared for a potentially volatile road ahead.
The Motley Fool August 3, 2007 Brian Lawler	Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit.
<Older 3981-3990 Newer> Return to current articles.